Compound bioogic component and pharmaceutical preparation possessing function for accelerating hemoglutination

A pharmaceutical preparation and a technology for promoting blood coagulation, applied in the field of new compound biological components, can solve the problems of transient increase in serum creatinine and indirect hemostasis, and achieve the effect of good hemostasis and less side effects

Inactive Publication Date: 2006-02-01
周长海
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, except for a small amount of traditional chemical drugs such as vitamin K, tranexamic acid, and carbacil, most of the clinically used hemostatic drugs are biochemical drugs, such as thrombin extracted from animal blood. This drug has certain limitations for local application. Aproti

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0040] A compound biological component with procoagulant effect and a preparation method thereof, characterized in that it comprises the following steps:

[0041] a. Thrombin-like extraction, separation, purification and refinement;

[0042] b. Thromboplastin-like extraction, separation, purification and identification;

[0043] c. The above biochemical components are compounded in a certain proportion to have a synergistic procoagulant and hemostatic effect, and mixed with an acceptable carrier to make a certain biochemical preparation;

[0044] d. Under GMP conditions, the finished product is freeze-dried.

[0045] The present invention also includes the freeze-dried injection prepared with the compound biological component of the present invention and an acceptable carrier and its application in hemostasis and the like.

[0046] The cold-dried powder injection formula of the present invention is composed as follows:

[0047] Thrombin-like 0.005-1IU Thromboplastin-like 0....

example

[0077] Prescription: thrombin-like 50IU, thrombin-like 1000IU

[0078] Mannitol 30g Albumin 0.2g Water for injection 1000ml

[0079] Packed into controlled vials, freeze-dried 1000 injections.

[0080] Preparation Process:

[0081] Take the prescribed amount of thrombin-like enzyme and thromboplastin-like enzyme respectively, add freshly cooled water for injection at 20-30°C and mix to form a concentrated solution, then dissolve the prescribed amount of excipients with water for injection, mix the above two solutions evenly and set volume to 1000ml, Adjust the pH to 6.0-7.0, and use a 10,000-molecular weight cut-off plate tangential flow ultrafilter to sterilize and remove pyrogens under 100-level purification conditions. 1ml vial contains 1 coagulation unit, half-stoppered into a freeze-drying box, pre-frozen at -35°C for 2 hours, and vacuumed to 10 -1 -10 -3 Gradually increase the temperature and sublimation drying under mmHg, so that the temperature of the shelf r...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A multi-component biochemical medicine with blood coagulating action for treating hemorrhage is prepared through extracting it from venin and is composed of thrombin-like enzyme and thrombin-like kinase. Said thrombin-like enzyme is the styptic norfibrase. Said thrombin-like kinase is the activator of blood coagulating X factor for activating the X factor in plasm to Xa and converting the thrombinogen to thrombase to treat hemorrhage.

Description

Technical field: [0001] The invention relates to a new compound biological component separated and extracted from snake venom with procoagulant effect. And new preparations made from it, freeze-dried injections, especially a compound biological component with procoagulant effect and its pharmaceutical preparations. Background technique: [0002] Clinically, bleeding caused by various etiologies is more common. Such as surgery and orthopedic surgery, gastrointestinal tract, kidney, bladder, prostate and chest surgery; invasive fracture bleeding, plastic surgery, brain swelling and pain, contusion bleeding. Internal medicine: liver disease hemorrhage, cancerous hemorrhage, hemorrhoids, pulmonary hemorrhage, epistaxis. Obstetrics and gynecology surgery, uterine and vaginal polyps, fibroids and cancer bleeding, bleeding after radiotherapy. Urology: Prostate bleeding, prostatectomy, kidney and bladder bleeding. Otorhinolaryngology: outpatient minor surgical prophylaxis, tonsi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/43A61K47/42A61K9/19A61K9/12A61K9/08A61P7/04
Inventor 周长海
Owner 周长海
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap